162 related articles for article (PubMed ID: 32330637)
21. Drifting policies are wasting billions.
Suh GH
Int Psychogeriatr; 2012 Mar; 24(3):343-5. PubMed ID: 22078134
[No Abstract] [Full Text] [Related]
22. Increased topical generic prices by manufacturers.
Bhatt MD; Bhatt BD; Dorrian JT; McLellan BN
J Am Acad Dermatol; 2019 May; 80(5):1353-1357. PubMed ID: 29544742
[TBL] [Abstract][Full Text] [Related]
23. Medicine, pharmacy, and industry--a fly's eye view of health care.
Halperin JA
Ann Pharmacother; 1995 Sep; 29(9):925-33. PubMed ID: 8547743
[No Abstract] [Full Text] [Related]
24. Pharmaceutical policy in Italy: towards a structural change?
Ghislandi S; Krulichova I; Garattini L
Health Policy; 2005 Apr; 72(1):53-63. PubMed ID: 15760698
[TBL] [Abstract][Full Text] [Related]
25. Variation in cash price of the generic medications most prescribed by dermatologists in pharmacies across the United States.
Alghanem N; Abokwidir M; Fleischer AB; Feldman SR; Alghanem W
J Dermatolog Treat; 2017 Mar; 28(2):119-128. PubMed ID: 27241622
[TBL] [Abstract][Full Text] [Related]
26. National trends in prescription drug expenditures and projections for 2021.
Tichy EM; Hoffman JM; Suda KJ; Rim MH; Tadrous M; Cuellar S; Clark JS; Wiest MD; Matusiak LM; Schumock GT
Am J Health Syst Pharm; 2021 Jul; 78(14):1294-1308. PubMed ID: 33880494
[TBL] [Abstract][Full Text] [Related]
27. Prior authorizations for dermatologic medications: An American Academy of Dermatology survey of US dermatology providers and staff.
Secrest AM; Asgari MM; Kourosh AS; Barbieri JS; Albrecht J;
J Am Acad Dermatol; 2017 Oct; 77(4):784-786. PubMed ID: 28917469
[No Abstract] [Full Text] [Related]
28. Antitrust, Market Exclusivity, and Transparency in the Pharmaceutical Industry.
Sinha MS; Curfman GD; Carrier MA
JAMA; 2018 Jun; 319(22):2271-2272. PubMed ID: 29801104
[No Abstract] [Full Text] [Related]
29. One lawyer's view of discriminatory pricing.
Wentz WH
Am Pharm; 1994 Oct; NS34(10):24-7, 42. PubMed ID: 7992788
[No Abstract] [Full Text] [Related]
30. Comparative experience in home care and pharmaceutical policy.
Kane NM; Saltman RB
Health Policy; 1997 Sep; 41 Suppl():S1-7. PubMed ID: 10174467
[No Abstract] [Full Text] [Related]
31. Evidence- or opinion-based pharmaceutical policy?
Lyles A
Clin Ther; 2004 Nov; 26(11):1922-3. PubMed ID: 15639703
[No Abstract] [Full Text] [Related]
32. Pricing medicines: theory and practice, challenges and opportunities.
Gregson N; Sparrowhawk K; Mauskopf J; Paul J
Nat Rev Drug Discov; 2005 Feb; 4(2):121-30. PubMed ID: 15688076
[TBL] [Abstract][Full Text] [Related]
33. Pharmaceuticals and medical devices: cost savings.
Steiner DJ
Issue Brief Health Policy Track Serv; 2013 Dec; ():1-32. PubMed ID: 24482891
[No Abstract] [Full Text] [Related]
34. The roles of the pharmaceutical industry and drug development in dermatology and dermatologic health care.
Altman DJ
Dermatol Clin; 2000 Apr; 18(2):287-96. PubMed ID: 10791155
[TBL] [Abstract][Full Text] [Related]
35. How to Reduce Prescription Drug Prices: First, Do No Harm.
Atlas S
Mo Med; 2020; 117(1):14-15. PubMed ID: 32158034
[No Abstract] [Full Text] [Related]
36. The Impact of Off-Patent Drug Acquisitions on Prices.
Gupta R; Henkel A; Forman HP; Ross JS
J Gen Intern Med; 2018 Jul; 33(7):1007-1009. PubMed ID: 29687433
[No Abstract] [Full Text] [Related]
37. Value-Based Pricing for Drugs: Theme and Variations.
Kaltenboeck A; Bach PB
JAMA; 2018 Jun; 319(21):2165-2166. PubMed ID: 29710320
[No Abstract] [Full Text] [Related]
38. Changes in Retail Prices of Prescription Dermatologic Drugs From 2009 to 2015.
Rosenberg ME; Rosenberg SP
JAMA Dermatol; 2016 Feb; 152(2):158-63. PubMed ID: 26606197
[TBL] [Abstract][Full Text] [Related]
39. RX for nosebleed prices.
Greenwald J
Time; 2001 May; 157(20):42-3. PubMed ID: 11383109
[No Abstract] [Full Text] [Related]
40. Generic drug firm settles claim that it was paid to stay out of market.
Dyer O
BMJ; 2015 Apr; 350():h2282. PubMed ID: 25920419
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
